Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 2,201 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 2,201 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $65,941.96. Following the completion of the sale, the general counsel now owns 105,555 shares of the company’s stock, valued at approximately $3,162,427.80. This represents a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $30.13 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $3.75 billion, a price-to-earnings ratio of -14.84 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The business has a 50 day simple moving average of $31.89 and a 200-day simple moving average of $33.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the firm earned ($1.17) EPS. The firm’s revenue for the quarter was up 78.3% on a year-over-year basis. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on APLS shares. Bank of America lowered their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Oppenheimer lowered their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Robert W. Baird reduced their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Scotiabank lowered their price target on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Finally, Piper Sandler cut their price objective on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of large investors have recently bought and sold shares of APLS. Envestnet Asset Management Inc. raised its position in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after purchasing an additional 39,931 shares during the period. JPMorgan Chase & Co. grew its stake in Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the last quarter. Profund Advisors LLC increased its position in Apellis Pharmaceuticals by 90.7% in the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock worth $1,648,000 after buying an additional 20,435 shares during the period. Algert Global LLC lifted its stake in Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after buying an additional 71,650 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals during the third quarter valued at $1,370,000. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).